Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Acta Haematol. 2012;127(1):20-2. doi: 10.1159/000330951. Epub 2011 Oct 12.

Efficacy of low-dose rituximab in a refractory acquired factor VIII inhibitor case secondary to pemphigus.

Author information

  • 1Department of Hematology, The First Affiliated Hospital, Harbin Medical University, China.

Abstract

Acquired factor VIII (FVIII) inhibitor induces a bleeding disorder caused by specific antibodies to FVIII. The cause of approximately one fifth of cases can be attributed to autoimmune disorders, such as pemphigus. Here, we describe a case of refractory acquired FVIII inhibitor in a patient with primary pemphigus and its successful treatment with low-dose rituximab. Coagulation studies revealed a prolonged activated partial thromboplastin time, which could not be corrected with the mixing test. At the same time, the FVIII activity level was significantly reduced, and the FVIII inhibitor titer was elevated. A treatment regimen with prednisolone/cyclophosphamide followed by prednisolone/cyclosporine was used. The patient temporarily responded but then became resistant to these medicines. However, subsequent treatment with low-dose rituximab achieved considerable clinical and laboratory improvement in the same patient. Follow-up at 6 months revealed a low level of residual FVIII inhibitor activity with normal coagulation functions. No drug-related side effects were detected. In conclusion, our results indicate that low-dose rituximab might be an effective and safe treatment for patients with acquired FVIII inhibitor.

Copyright © 2011 S. Karger AG, Basel.

PMID:
21996575
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Write to the Help Desk